378 related articles for article (PubMed ID: 11583940)
1. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
3. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.
Shaffer D; Langone A; Nylander WA; Goral S; Kizilisik AT; Helderman JH
Clin Transplant; 2003; 17 Suppl 9():31-4. PubMed ID: 12795665
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
5. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
Tsai SF; Cheng CY; Shu KH; Wu MJ
Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
[TBL] [Abstract][Full Text] [Related]
6. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
7. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
8. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
9. Minimizing calcineurin inhibitor drugs in renal transplantation.
Flechner SM
Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
[TBL] [Abstract][Full Text] [Related]
10. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.
Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA
Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
12. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
14. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
Morales JM
Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
[TBL] [Abstract][Full Text] [Related]
16. Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors.
Lisik W; Kahan BD
Transplant Proc; 2006; 38(1):69-73. PubMed ID: 16504667
[TBL] [Abstract][Full Text] [Related]
17. Conversion to sirolimus in a population of kidney and kidney-pancreas transplant recipients.
Almeida M; Martins LS; Dias L; Figueiredo MJ; Henriques AC; Sarmento AM; Cabrita A
Transplant Proc; 2005; 37(6):2777-80. PubMed ID: 16182808
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
Olyaei AJ; de Mattos AM; Bennett WM
Curr Opin Crit Care; 2001 Dec; 7(6):384-9. PubMed ID: 11805539
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
Chatel MA; Larkin DF
Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.
Groetzner J; Kaczmarek I; Meiser B; Müller M; Daebritz S; Reichart B
J Heart Lung Transplant; 2004 Jun; 23(6):770-3. PubMed ID: 15366440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
